Summary of project PR002345
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR002345. The data can be accessed directly via it's Project DOI: 10.21228/M8HN9H This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
| Project ID: | PR002345 |
| Project DOI: | doi: 10.21228/M8HN9H |
| Project Title: | Stable-label palmitate tracing of gemcitabine-based chemotherapy in PDAC cells |
| Project Summary: | Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease with few treatment options and poor survivability. In this work we sought to characterise metabolic adaptations to gemcitabine (GEMC)-based chemotherapy exposure to discover new therapeutic targets for improving treatment efficacy. We show that GEMC resistance (GEMR) upregulates de novo lipogenesis in Panc1 and MiaPaCa2 cells. |
| Institute: | Victor Chang Cardiac Research Institute |
| Last Name: | Hancock |
| First Name: | Sarah |
| Address: | Level 7 Lowy Packer Building, 405 Liverpool Street, Darlinghurst, NSW 2010, Australia |
| Email: | s.hancock@victorchang.edu.au |
| Phone: | +61414537526 |
Summary of all studies in project PR002345
| Study ID | Study Title | Species | Institute | Analysis(* : Contains Untargted data) | Release Date | Version | Samples | Download(* : Contains raw data) |
|---|---|---|---|---|---|---|---|---|
| ST003762 | Stable-label palmitate tracing of gemcitabine-based chemotherapy in PDAC cells | Homo sapiens | Victor Chang Cardiac Research Institute | MS | 2025-03-21 | 1 | 52 | Uploaded data (34.5G)* |
